Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Astex Therapeutics Limited
Astex Therapeutics Limited_20100107
Astex Therapeutics Limited_20100128
  

Astex Therapeutics Limited patents

Recent patent applications related to Astex Therapeutics Limited. Astex Therapeutics Limited is listed as an Agent/Assignee. Note: Astex Therapeutics Limited may have other listings under different names/spellings. We're not affiliated with Astex Therapeutics Limited, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Astex Therapeutics Limited-related inventors




Date Astex Therapeutics Limited patents (updated weekly) - BOOKMARK this page
08/10/17Bicyclic heterocycle compounds and their uses in therapy
04/20/17New compounds
02/02/17Bicyclic heterocycle compounds and their uses in therapy
01/05/17Quinolines as fgfr kinase modulators
01/05/17Pteridines as fgfr inhibitors
08/18/16Substituted pyrido[2,3-b]pyrazines as fgfr kinase inhibitors
08/04/16Substitutued quinoxalines as fgfr kinase inhibitors
07/28/16New compounds
04/21/16Naphthyridine derivative compounds
03/24/16Bicyclic heterocycle compounds and their uses in therapy
03/17/16Quinazolinone derivatives useful as fgfr kinase modulators
12/10/15Bicyclic heterocycle compounds and their uses in therapy
10/15/15Bicyclic heterocycle compounds and their uses in therapy
10/15/15Pteridines as fgfr inhibitors
09/24/15Bicyclic heterocycle compounds and their uses in therapy
09/17/15Bicyclic heterocycle compounds and their uses in therapy
08/27/15New compounds
02/26/15New compounds
02/19/15Pharmaceutical compounds
02/12/15Hydroxybenzamide derivatives and their use as inhibitors of hsp90
01/29/15Anticancer benzopyrazines via the inhibition of fgfr kinases
10/02/14Quinolines as fgfr kinase modulators
09/25/14Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
09/25/14Anticancer pyridopyrazines via the inhibition of fgfr kinases
06/26/14Bicyclic heterocycle compounds and their uses in therapy
02/13/14Bicyclic heterocycle compounds and their uses in therapy
01/09/14Benzimidazole derivatives and their use as protein kinase inhibitors
10/10/13Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases
08/15/13Pharmaceutical compounds
03/21/13Pyrazolyl quinazoline kinase inhibitors
08/16/12Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
07/26/12Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
02/16/12Imidazo [1,2-a]pyridine derivatives as fgfr kinase inhibitors for use in therapy
02/09/12Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
02/09/12Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
02/09/12Bicyclic heterocyclyl derivatives as fgfr kinase inhibitors for therapeutic use
11/10/114-(2,6-dichloro-benzoylamino)-1h-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors
09/15/11Benzimidazole derivatives and their use as protein kinase inhibitors
06/30/11Pharmaceutical combinations
06/30/11Recombinant alpha-fetoprotein and compositions thereof
05/05/11Pharmaceutical combinations
01/06/11Combinations of pyrazole kinase inhibitors
12/30/10Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
11/11/10Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
08/19/10Aryl-alkylamines and heteroaryl-alkylamines as protein kinase inhibitors
06/24/10Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
06/17/10Pharmaceutical compounds
05/13/10Bicyclic heterocyclic compounds as fgfr inhibitors
03/04/10Pharmaceutical combinations of 1-cyclopropyl-3- [3-(5-m0rphoolin-4-yl-methyl-1h-benzoimidazol-2-yl)- lh-1-pyrazol-4-yl]- urea
01/28/10Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
01/07/10Pharmaceutical compounds
12/24/09Medical use of cyclin dependent kinases inhibitors
12/24/094-(2, 6-dichloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the treatment of cancer
10/22/09Pharmaceutical combinations
09/17/09Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer's disease, neurodegeneration and dementia
09/17/09New compounds 834
08/27/09Hydroxybenzamide derivatives and their use as inhibitors of hsp90
07/09/09Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer's disease, neurodegeneration and dementia
06/04/09Pharmaceutical combinations of diazole derivatives for cancer treatment
02/05/09Pharmaceutical compounds
01/28/10Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
01/07/10Pharmaceutical compounds







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Astex Therapeutics Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Astex Therapeutics Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';